Plísková Martina, Vondrácek Jan, Vojtesek Borivoj, Kozubík Alois, Machala Miroslav
Department of Chemistry and Toxicology, Veterinary Research Institute, 621 32 Brno, Czech Republic.
Toxicol Sci. 2005 Feb;83(2):246-56. doi: 10.1093/toxsci/kfi040. Epub 2004 Nov 17.
Polycyclic aromatic hydrocarbons (PAHs), such as benzo[a]pyrene (BaP), are carcinogens suggested to be involved in development of human cancer. Several recent studies have reported that PAHs can activate estrogen receptors (ER), either directly or indirectly by producing estrogenic metabolites. We hypothesized that the activation of ER by PAHs or their metabolites could induce cell proliferation in estrogen-sensitive cells. In the present study, we found that two PAHs, benz[a]anthracene (BaA) and BaP, can stimulate proliferation of human breast carcinoma MCF-7 cells at concentrations 100 nM and higher. This effect was ER-dependent, because it was blocked by the pure antiestrogen ICI 182,780. Although both PAHs partially inhibited S-phase entry and DNA synthesis induced by 17beta-estradiol, they stimulated S-phase entry when applied to MCF-7 cells synchronized by serum deprivation. This was in contrast with model antiestrogenic aryl hydrocarbon receptor ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin, which fully suppressed S-phase entry. BaP, which is a strong mutagen, was found to induce p53 tumor suppressor expression, a partial S-phase arrest and at higher concentrations also cell death. Pifithrin-alpha, a synthetic inhibitor of p53 activity, abolished both S-phase arrest and apoptosis induced by genotoxic PAHs, and it potentiated the proliferative effect of BaP. Thus, both genotoxic and nongenotoxic events seem to interact in the effects of BaP on cell proliferation. Taken together, our data indicate that both BaA and BaP can stimulate cell proliferation through activation of ER. The proliferative effects of these carcinogenic compounds might contribute to tumor promotion in estrogen-sensitive tissues.
多环芳烃(PAHs),如苯并[a]芘(BaP),是被认为与人类癌症发生有关的致癌物。最近的几项研究报告称,PAHs可直接或通过产生雌激素代谢物间接激活雌激素受体(ER)。我们假设PAHs或其代谢物对ER的激活可诱导雌激素敏感细胞的增殖。在本研究中,我们发现两种PAHs,苯并[a]蒽(BaA)和BaP,在浓度为100 nM及以上时可刺激人乳腺癌MCF-7细胞的增殖。这种效应依赖于ER,因为它被纯抗雌激素ICI 182,780阻断。尽管两种PAHs都部分抑制了17β-雌二醇诱导的S期进入和DNA合成,但当应用于通过血清剥夺同步化的MCF-7细胞时,它们刺激了S期进入。这与模型抗雌激素芳烃受体配体2,3,7,8-四氯二苯并对二恶英相反,后者完全抑制了S期进入。BaP是一种强诱变剂,被发现可诱导p53肿瘤抑制因子表达、部分S期停滞,且在较高浓度下还可导致细胞死亡。p53活性的合成抑制剂匹非尼酮-α消除了基因毒性PAHs诱导的S期停滞和凋亡,并增强了BaP的增殖效应。因此,基因毒性和非基因毒性事件似乎在BaP对细胞增殖的影响中相互作用。综上所述,我们的数据表明BaA和BaP均可通过激活ER来刺激细胞增殖。这些致癌化合物的增殖作用可能有助于雌激素敏感组织中的肿瘤促进。